Development of highly effective LCB1-based lipopeptides targeting the spike receptor-binding motif of SARS-CoV-2.

Authors:
Zhu Y; Li M; Liu N; Wu T; Han X and 2 more

Journal:
Antiviral Res

Publication Year: 2023

DOI:
10.1016/j.antiviral.2023.105541

PMCID:
PMC9851916

PMID:
36682464

Journal Information

Full Title: Antiviral Res

Abbreviation: Antiviral Res

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Anti-Infective Agents

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure statement No potential conflict of interest was reported by the authors. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

Evidence found in paper:

"We thank Linqi Zhang at the Tsinghua university (Beijing, China) for providing the plasmids that encode the mutant S proteins of SARS-CoV-2 VOCs. This work was supported by grants from the 10.13039/501100001809National Natural Science Foundation of China (822210040, 82230076) and the CAMS Innovation Fund for Medical Sciences (2021-I2M-1037)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025